288 completed, 23 terminated, 19 unknown, 16 recruiting. 370 Phase 1, 60 Phase 2.
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia Brexpiprazole, Cariprazine, [11C] PHNO - Schizoaffective Disorder, Schizophreniform Disorder | Phase 1 | Not yet recruiting | New York State Psychiatric Institute | 100 | 2026-12-01 | 2026-07-20 |
| Xingqi Daozhi Decoction for Antipsychotic-Induced Constipation Xingqi Daozhi Decoction, Placebo Group - Schizophrenia, Antipsychotic Drug | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Mental Health Center | 46 | 2026-12-01 | 2026-11-10 |
| Phase I Trial of HHK101 in Patients With Schizophrenia HHK101-Single Dose 1, HHK101-Single Dose 2, HHK101-Single Dose 3 - Schizophrenia | Phase 1 | Not yet recruiting | Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd. | 88 | 2026-11-15 | 2026-11-02 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia XEP527, Placebo - Schizophrenia | Phase 1 | Recruiting | Novartis Pharmaceuticals | 36 | 2026-11-04 | 2026-11-09 |
| A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults 14C-SEP-380135 - Schizophrenia | Phase 1 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | 2026-11-01 | 2026-10-16 |
| Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants NRL-1004 2.5 mg, ZYPREXA IM 10mg, NRL-1004 5.0 mg - Healthy Adult Participants | Phase 1 | Not yet recruiting | Neurelis, Inc. | 24 | 2026-10-16 | 2026-11-06 |
| Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia AX251 LAI 45 mg, AX251 LAI 90 mg, AX251 LAI 135 mg - Schizophrenia | Phase 1 | Recruiting | Anxo Pharmaceutical Co., Ltd. | 48 | 2026-09-14 | 2026-09-16 |
| A Cognitive Mobile Intervention for Motivation in Psychotic Disorders Cognitive Training, Mobile cognitive training - Schizophrenia / Schizoaffective Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 45 | 2026-09-01 | 2026-06-30 |
| A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia LTX-001 once daily, Placebo, LTX-001 twice daily - Schizophrenia | Phase 1 | Recruiting | Leal Therapeutics, Inc | 90 | 2026-08-03 | 2026-09-17 |
| A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398 SIPI6398 Tablets - Schizophrenia Disorder | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Zhongze Therapeutics Co., Ltd. | 9 | 2026-08-01 | 2026-06-04 |
| Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life Study Ecological Momentary Assessment (EMA) and Reality Monitoring tasks - Schizophrenia | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Charles Perrens, Bordeaux | 120 | 2026-06-01 | 2026-03-16 |
| A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects KR23248, Matching Placebo - Schizophrenia | Phase 1 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 66 | 2026-05-19 | 2026-05-15 |
| A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia Aticaprant, Placebo - Schizophrenia | Phase 1 | Recruiting | Janssen Research & Development, LLC | 64 | 2026-03-02 | 2026-11-03 |
| A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT KarXT - Schizophrenia | Phase 1 | Recruiting | Bristol-Myers Squibb | 131 | 2025-09-03 | 2026-09-02 |
| A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 LY03020, Placebo - Schizophrenia, Alzheimer's Disease Psychosis | Phase 1 | Recruiting | Luye Pharma Group Ltd. | 40 | 2025-08-20 | 2025-11-19 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine Cariprazine Depot, Cariprazine Depot MTD, Oral Cariprazine 3 mg/day - Schizophrenia, Bipolar I Disorder | Phase 1 / Phase 2 | Recruiting | Mapi Pharma Ltd. | 24 | 2025-08-01 | 2026-05-01 |
| A Food Effect Study of LY03020 in Healthy Subjects LY03020 - Schizophrenia, Alzheimer's Disease Psychosis | Phase 1 | Active not recruiting | Luye Pharma Group Ltd. | 16 | 2025-07-30 | 2025-12-18 |
| Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpiprazole) Brexpiprazole Film Coated Tablets, RXULTI film coated tablet - Schizophrenia | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 36 | 2025-06-22 | 2025-12-05 |
| The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression., Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD, Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. - Anxiety, Depression | Phase 1 | Completed | Rakitzi, Stavroula | 107 | 2025-06-02 | 2026-08-04 |
| A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women SEP-380135, Quinidine Gluconate - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | 2025-03-07 | 2026-01-15 |
Showing 20 of 370. Sign in to see all of them.
Psychotic Disorders (80) · Mood Disorders (23) · Bipolar Disorder (16) · Mental Disorders (10) · Cognitive Dysfunction (6) · Alzheimer Disease (4) · Depressive Disorder, Major (4) · Marijuana Abuse (3) · Psychomotor Agitation (3) · Schizophrenia Spectrum and Other Psychotic Disorders (3) · Anxiety Disorders (2) · Autism Spectrum Disorder (2) · Cognition Disorders (2) · Depression (2)
Schizophrenia Spectrum and Other Psychotic Disorders (367) · Mental Disorders (360) · Mood Disorders (17) · Nervous System Diseases (17) · Bipolar and Related Disorders (16) · Pathological Conditions, Signs and Symptoms (16) · Signs and Symptoms (13) · Neurologic Manifestations (11) · Neurocognitive Disorders (10) · Behavior (9) · Central Nervous System Diseases (9) · Chemically-Induced Disorders (7) · Behavioral Symptoms (6) · Brain Diseases (6) · Cognition Disorders (6)
Paliperidone Palmitate (21) · Risperidone (21) · Aripiprazole (17) · Olanzapine (16) · SEP-363856 (12) · Ketamine (8) · Lurasidone Hydrochloride (8) · Quetiapine Fumarate (7) · MK-8189 (6) · Transcranial Direct Current Stimulation (6) · Moxifloxacin (5) · PF-04958242 (5) · Saline Solution (5) · brexpiprazole (5) · iloperidone (5)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (31) · Otsuka Pharmaceutical Development & Commercialization, Inc. (29) · GlaxoSmithKline (15) · Wyeth is now a wholly owned subsidiary of Pfizer (11) · Luye Pharma Group Ltd. (9) · Pfizer (8) · Yale University (8) · Merck Sharp & Dohme LLC (7) · New York State Psychiatric Institute (6) · Sumitomo Pharma America, Inc. (6) · Biogen (5) · H. Lundbeck A/S (5) · Hoffmann-La Roche (5) · Alkermes, Inc. (4) · Autifony Therapeutics Limited (4)
United States (211) · United Kingdom (24) · China (22) · Spain (10) · Germany (8) · Israel (7) · Japan (7) · Canada (6) · Belgium (5) · Croatia (5) · India (5) · Pakistan (5) · South Korea (5) · Australia (4) · Brazil (3)
Robert Freedman, MD (5) · Gang Wang (3) · Takehisa Matsumaru (3)
PMID 38244179, PMID 22992330, PMID 26493637, PMID 28204607, PMID 28350572, PMID 28695535, PMID 32141724, PMID 41034820, PMID 17355521, PMID 18227146, PMID 18626272, PMID 19915181, PMID 20537128, PMID 20537130, PMID 20584515, PMID 22160487, PMID 22383949, PMID 22452559, PMID 22455454, PMID 22513041, PMID 22717030, PMID 22766391, PMID 23822566, PMID 24419307, PMID 24423017, PMID 25563714, PMID 25693889, PMID 25735992, PMID 26011657, PMID 26072311, PMID 26116126, PMID 26306819, PMID 26631428, PMID 26911397, PMID 27089154, PMID 27136907, PMID 27333588, PMID 27371157, PMID 27617637, PMID 27655012, PMID 27743205, PMID 27871302, PMID 28318835, PMID 28597226, PMID 28845238, PMID 28965778, PMID 29103081, PMID 29177699, PMID 30348514, PMID 30509308
2017 (2), U01MH094247 (2), 1DP5OD036172-01 (1), 2008 (1), 2014 (1), 2015 (1), 2016 (1), 2019 (1), 2023 (1), I01CX001414 (1), K23DA018203 (1), R01DA013196 (1), R01DA026799 (1), R01DA034699 (1), R01MH059101 (1)